Vanda’s New Schizophrenia Drug Offers the Company a Way Out of Medicaid Inflation Penalties
And a new paper makes clear how quickly Chinese biopharma has risen
Mar 27, 2026
Subscribe to Cost Curve Apex to read the rest.
Upgrade to Apex to get access to this post and other subscriber-only content.
Upgrade